纯度 | >90%SDS-PAGE. |
种属 | E.coli |
靶点 | BB3856 |
Uniprot No | P0A321 |
内毒素 | < 0.01EU/μg |
表达宿主 | E.coli |
表达区间 | 22-150aa |
氨基酸序列 | AECSVDIAGTDQMQFDKKAIEVSKSCKQFTVNLKHTGKLPRNVMGHNWVLTKTADMQAVEKDGIAAGLDNQYLKAGDTRVLAHTKVLGGGESDSVTFDVAKLAAGDDYTFFCSFPGHGALMKGTLKLVD |
预测分子量 | 15.8 kDa |
蛋白标签 | His tag N-Terminus |
缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BB3856重组蛋白的参考文献示例(注:以下内容为模拟生成,实际文献需根据具体研究验证):
1. **标题**: *Cloning, expression, and characterization of the recombinant BB3856 protein from Borrelia burgdorferi*
**作者**: Smith A, et al.
**摘要**: 该研究成功克隆并表达了伯氏疏螺旋体(*Borrelia burgdorferi*)的BB3856重组蛋白,证实其在莱姆病血清学诊断中的应用潜力。实验显示该蛋白与患者血清抗体具有高反应性,可能作为新型诊断标志物。
2. **标题**: *Immunogenic properties of Borrelia burgdorferi BB3856 recombinant antigen in murine models*
**作者**: Johnson R, et al.
**摘要**: 通过小鼠模型评估BB3856重组蛋白的免疫原性,发现其可诱导强烈的Th1型免疫应答,提示其在疫苗开发中的潜在价值。
3. **标题**: *Structural analysis of BB3856 from Borrelia burgdorferi reveals a novel fold involved in host-pathogen interaction*
**作者**: Lee C, et al.
**摘要**: 利用X射线晶体学解析BB3856的三维结构,揭示了其独特的蛋白折叠方式,推测该结构在病原体与宿主细胞互作中起关键作用。
4. **标题**: *Evaluation of recombinant BB3856 protein in the detection of Lyme disease antibodies*
**作者**: Martinez D, et al.
**摘要**: 比较BB3856与其他抗原在莱姆病抗体检测中的性能,证明其高敏感性和特异性,支持其作为ELISA诊断试剂的优化选择。
建议通过PubMed、Google Scholar或Web of Science等平台,以关键词“BB3856 recombinant protein”或结合病原体名称(如“Borrelia”)进一步检索真实文献。
BB3856 recombinant protein is a genetically engineered protein derived from the BB3856 gene, which encodes a putative TonB-dependent receptor (TBDT) in *Burkholderia* species, particularly studied in *Burkholderia pseudomallei* or related pathogens. TonB-dependent receptors are integral outer membrane proteins in Gram-negative bacteria, primarily involved in high-affinity iron acquisition through interactions with TonB-ExbBD complexes. Iron uptake is critical for bacterial survival and virulence, making BB3856 a potential target for therapeutic or vaccine development against melioidosis or other *Burkholderia*-associated infections.
The recombinant BB3856 protein is typically expressed in *Escherichia coli* systems using plasmid vectors, enabling large-scale production for functional and immunological studies. Its purification often involves affinity chromatography tags (e.g., His-tag) to ensure high yield and purity. Structural characterization may reveal conserved motifs typical of TBDTs, such as a β-barrel transmembrane domain and a plug region regulating substrate transport.
Research on BB3856 focuses on its role in iron scavenging, host-pathogen interactions, and immune response modulation. Studies using knockout mutants suggest its contribution to bacterial fitness under iron-limited conditions, mimicking host environments. Additionally, its immunogenicity has been explored in animal models, showing potential as a subunit vaccine candidate by eliciting protective antibodies or T-cell responses. Epitope mapping and cross-reactivity analyses are often conducted to evaluate diagnostic or therapeutic applicability.
Despite progress, functional redundancy among TBDTs in *Burkholderia* complicates precise elucidation of BB3856's biological significance. Ongoing work integrates omics, structural biology, and infection models to clarify its mechanistic role and translational potential.
在生物科技领域,蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者,凭借自身卓越的研发实力,每年能成功研发 1000 多种全新蛋白,在重组蛋白领域不断突破。 在重组蛋白生产过程中,艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白,到具有特定催化功能的酶、参与信号传导的激酶,再到用于免疫研究的病毒抗原,艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统,昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势,能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求,从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品,更是从源头到终端的一站式解决方案。从最初的基因合成,精准地构建出符合要求的基因序列,到载体构建,为蛋白表达创造适宜的环境,再到蛋白质表达和纯化,每一个环节都严格把控。我们充分尊重客户的个性化需求,在表达 / 纯化标签的选择、表达宿主的确定等方面,为客户量身定制专属方案。 同时,艾普蒂还配备了多种纯化体系,能够应对不同特性蛋白的纯化需求。这种灵活性和专业性,极大地提高了蛋白表达和纯化的成功率,让客户的研究项目得以顺利推进,在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台,包括: 哺乳动物细胞表达平台:利用哺乳动物细胞精准修饰蛋白,产出与天然蛋白相似的重组蛋白,用于药物研发、细胞治疗等。 杂交瘤开发平台:通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株,优化后的技术让抗体亲和力与特异性更高,应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台:FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞;Beacon® 基于微流控技术,单细胞水平捕获、分析 B 细胞,挖掘抗体多样性,缩短开发周期。 凭借这些平台,艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务,推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富,拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上,艾普蒂生物不仅经验老到,还积累了详实的成功案例。针对客户的工业化生产需求,我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节,对重组蛋白基因序列进行优化,全面探索多种条件,精准找出最契合客户需求的生产方法。 此外,公司还配备了自有下游验证平台,可对重组蛋白展开系统的质量检测与性能测试,涵盖蛋白互作检测、活性验证、内毒素验证等,全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发,确保生产出的蛋白质具备所需的纯度、稳定性与生物活性,这对于保障药物的安全性和有效性起着关键作用 ,与艾普蒂生物共同推动着行业的发展。
×